CODEXIS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CODEXIS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $138.59M | Feb 27, 2023 |
| FY2022 | Dec 31, 2021 | $104.75M | Feb 27, 2023 |
| FY2022 | Dec 31, 2020 | $69.06M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $68.46M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $60.59M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $50.02M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $48.84M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $41.80M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $35.31M | Mar 9, 2017 |
| FY2013 | Dec 31, 2013 | $9.53M | Mar 13, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.39M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $59.35M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $70.14M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $138.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $104.75M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $69.06M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $68.46M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $60.59M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $50.02M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $48.84M | Mar 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.97M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($65.28M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | ($76.24M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | ($33.59M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($21.28M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($24.01M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($11.94M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($10.88M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($23.00M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($8.56M) | Mar 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.74M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($58.52M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | ($68.07M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | ($34.88M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($22.70M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($23.92M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($12.55M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($11.30M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($22.97M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($8.56M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.31M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $46.26M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $58.89M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $80.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.92M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $44.19M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $33.87M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $29.98M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $29.66M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $22.23M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.07M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $55.15M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $53.25M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $52.17M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $49.32M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $35.05M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $31.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $29.29M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $29.01M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $25.42M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.38M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($49.41M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | ($52.64M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $11.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($14.27M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($16.46M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($12.56M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($14.09M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($8.76M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($1.86M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.47M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.31M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $4.42M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $8.31M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $13.83M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.75M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.73M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.77M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $985.0K | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $888.0K | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.80M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $149.01M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $136.56M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $250.39M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $246.38M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $221.65M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $149.07M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $79.28M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $53.63M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $35.65M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.27M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $82.08M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $49.95M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $105.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $81.99M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $51.54M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $43.56M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $22.98M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $29.08M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $16.55M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.53M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $66.93M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $86.62M | Mar 11, 2026 |
| FY2025 | Dec 31, 2022 | $144.80M | Mar 11, 2026 |
| FY2024 | Dec 31, 2021 | $164.39M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $170.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $105.52M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $56.31M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $24.55M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $19.10M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.46M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.46M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $2.46M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $3.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.24M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $3.24M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.24M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $3.24M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $3.24M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.24M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($606.78M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($562.81M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($497.53M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($421.29M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($387.70M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($366.42M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($342.41M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($330.47M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($315.07M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($292.07M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.79M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $19.26M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $65.12M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $113.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $116.80M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $149.12M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $90.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $53.04M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $31.22M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $19.24M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.11M | Mar 11, 2026 |
| FY2024 | Dec 31, 2024 | $28.91M | Feb 27, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.48M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 81.85M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 69.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 65.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 65.11M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 64.28M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 58.88M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 54.07M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 48.37M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 41.26M | Mar 15, 2018 |